Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, March 28, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

Pfizer, as successor to Wyeth Pharmaceuticals, inflated share price by false and misleading statements about an Alzheimer's drug, B-Mab, and the share price dropped by 12 percent in a day when the truth came out, shareholders claim in Newark Federal Court.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...